VYNE Therapeutics Inc.VYNENASDAQ
Loading
Gross Profit Growth Under PressureDecelerating
Percentile Rank32
Year-over-Year Change
Year-over-year gross profit growth rate
Percentile
P32
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -26.04% |
| Q3 2025 | 144.93% |
| Q2 2025 | -65.84% |
| Q1 2025 | 140.48% |
| Q4 2024 | -30.58% |
| Q3 2024 | -38.89% |
| Q2 2024 | 102.04% |
| Q1 2024 | 28.95% |
| Q4 2023 | -33.33% |
| Q3 2023 | -15.56% |
| Q2 2023 | 36.36% |
| Q1 2023 | 1550.00% |
| Q4 2022 | -96.41% |
| Q3 2022 | 32.54% |
| Q2 2022 | -29.21% |
| Q1 2022 | -87.19% |
| Q4 2021 | 1222.86% |
| Q3 2021 | -60.67% |
| Q2 2021 | 16.09% |
| Q1 2021 | -93.87% |
| Q4 2020 | 29.47% |
| Q3 2020 | -74.74% |
| Q2 2020 | 675.66% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 100.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | -100.00% |
| Q2 2018 | 1940.85% |
| Q1 2018 | -82.09% |
| Q4 2017 | 205.28% |
| Q3 2017 | 102.45% |
| Q2 2017 | 0.00% |
| Q1 2017 | -0.22% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |